MTBT
MTBT is an anticancer agent and p38 MAPK activator. MTBT can inhibit tumor cell proliferation, induce cell cycle arrest and apoptosis. MTBT increases the phosphorylation of histone H3 serine in cancer cells, thereby arresting the cell cycle in the M phase. The specific inhibitor of p38 MAPK, Adezmapimod , can abrogate the cell cycle arrest induced by MTBT[1].
Product Specifications
CAS Number
1110905-26-4
UNSPSC
12352005
Target
Apoptosis; p38 MAPK
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mtbt.html
Purity
99.60
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1=CC=C(C=C1O)C2=CSC(C3=C(C=CS3)C)=N2
Molecular Formula
C14H11NO2S2
Molecular Weight
289.37
References & Citations
[1]Li Y, et al. A small molecule, MTBT, prevents cancer cell growth by activating p38 MAPK. Anticancer Drugs. 2014 Apr;25 (4) :423-32.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Rho GDP Dissociation Inhibitor Alpha (ARHGDIa) ELISA Kit
Human Rho GDP Dissociation Inhibitor Alpha (ARHGDIa) ELISA Kit
TLE1 (Synovial Sarcoma Marker) (TLE1/2085), CF594 conjugate, 0.1mg/mL
